Anti-CD19 ADCC Enhanced Antibody (MDX-1342) is an ADCC enhanced antibody produced by our Afuco™ platform. MDX-1342 is a fully human monoclonal antibody (HuMAb) with enhanced antibody-dependent cellular cytotoxicity (ADCC) effector function, targeting CD19-membrane receptor which is highly expressed on malignant chronic lymphocytic leukemia (CLL) cells.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
AGTO-L047E | anti-CD19 immunotoxin HD37 (scFv)-PE | Cytotoxicity assay, Functional assay | |
AGTO-L047D | anti-CD19 immunotoxin HD37 (scFv)-DT | Cytotoxicity assay, Functional assay | |
AGTO-L047R | anti-CD19 immunotoxin HD37 (scFv)-RTA | Cytotoxicity assay, Functional assay | |
AGTO-L047S | anti-CD19 immunotoxin HD37 (scFv)-Sap | Cytotoxicity assay, Functional assay | |
AGTO-L047P | anti-CD19 immunotoxin HD37 (scFv)-PAP | Cytotoxicity assay, Functional assay |
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.